{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:42:26Z","timestamp":1784072546770,"version":"3.55.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"NovoNordisk Health Care AG","award":["# CHE-101.209.164"],"award-info":[{"award-number":["# CHE-101.209.164"]}]},{"name":"German Primary Hyperoxaluria Self"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>Defective hepatic alanine-glyoxylate aminotransferase (AGT) leads to oxalate overproduction in primary hyperoxaluria type 1 (PH1). Nedosiran and lumasiran are RNA interference (RNAi) agents inhibiting oxalate production. In PH1 patients with kidney failure, isolated kidney transplantation (iKTx) might be possible with RNAi medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report on 17 PH1 patients on hemodialysis, who received lumasiran (7 patients, 1\u201368 years, 6 females), lumasiran post-nedosiran (2 patients, both 6.5 years, male), double RNAi (dRNAi) (4 patients, 37 years, 3 infants, all male) and nedosiran (4 patients, 11\u201358 years, 2 female). Plasma oxalate (Pox) pre-HD was measured and systemic oxalate grading (SOG) was evaluated mainly by bone magnetic resonance imaging and speckle echocardiography, before the start of and repeatedly during treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In four patients iKTx was performed, being successful or with recurrence in two patients each. In others, development of Pox values under RNAi treatment and thus SOG increment and clinical deterioration were profound arguments for transplant decisions. Based on that, iKTx is now planned in five and liver\/kidney Tx in four patients (one liver already transplanted). Three patients have died.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pox should not be the sole parameter by which to decide on Tx procedure. In patients with minor oxalate deposition, no SOG deterioration and sensitivity to vitamin B6 or under efficacious RNAi treatment, iKTx can be considered. Severe (and deteriorating) systemic oxalosis, high Pox during RNAi treatment and maximum dialysis should lead to reconsidering combined or sequential LKTx rather than iKTx. Patients with severe systemic oxalosis at time of diagnosis still have a high mortality rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf202","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:10:04Z","timestamp":1759320604000},"page":"736-749","source":"Crossref","is-referenced-by-count":5,"title":["RNA interference medication and transplantation procedures in patients with primary hyperoxaluria type\u00a01"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-4642","authenticated-orcid":false,"given":"Cristina","family":"Martin-Higueras","sequence":"first","affiliation":[{"name":"German Hyperoxaluria Center , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8402-1325","authenticated-orcid":false,"given":"Lodovica","family":"Borghese","sequence":"additional","affiliation":[{"name":"German Hyperoxaluria Center , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-8656","authenticated-orcid":false,"given":"Jens","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"University Hospital Muenster, Pediatric Nephrology , Muenster ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-3158","authenticated-orcid":false,"given":"Caroline","family":"Kempf","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Berlin, Pediatric Nephrology , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4131-2273","authenticated-orcid":false,"given":"Britta","family":"H\u00f6cker","sequence":"additional","affiliation":[{"name":"University Children\u2019s Hospital Heidelberg University, Medical Faculty, Department of Pediatrics I, , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-8275","authenticated-orcid":false,"given":"Henry","family":"Fehrenbach","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Klinikum Memmingen, Pediatric Nephrology , Memmingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8834-6414","authenticated-orcid":false,"given":"Adam","family":"Walli","sequence":"additional","affiliation":[{"name":"Wisplinghoff Lab , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1740-0006","authenticated-orcid":false,"given":"Mark","family":"Born","sequence":"additional","affiliation":[{"name":"Pediatric Radiology, University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-2675","authenticated-orcid":false,"given":"Katharina","family":"Linden","sequence":"additional","affiliation":[{"name":"Pediatric Cardiology, University Hospital Aachen , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8120-3306","authenticated-orcid":false,"given":"Bernd","family":"Hoppe","sequence":"additional","affiliation":[{"name":"German Hyperoxaluria Center , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"2026033111013396000_bib1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N Engl J Med"},{"key":"2026033111013396000_bib2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/0014-5793(86)80563-4","article-title":"Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I","volume":"201","author":"Danpure","year":"1986","journal-title":"FEBS Lett"},{"key":"2026033111013396000_bib3","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1083\/jcb.111.6.2341","article-title":"Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine\/glyoxylate aminotransferase in primary hyperoxaluria type 1","volume":"111","author":"Purdue","year":"1990","journal-title":"J Cell Biol"},{"key":"2026033111013396000_bib4","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s40265-022-01735-x","article-title":"Improving treatment options for primary hyperoxaluria","volume":"82","author":"Hoppe","year":"2022","journal-title":"Drugs"},{"key":"2026033111013396000_bib5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrneph.2012.113","article-title":"An update on primary hyperoxaluria","volume":"8","author":"Hoppe","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2026033111013396000_bib6","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14003","article-title":"Combined liver kidney transplantation for primary hyperoxaluria type 1: will there still be a future? Current transplantation strategies and monocentric experience","volume":"25","author":"Tandoi","year":"2021","journal-title":"Pediatr Transplant"},{"key":"2026033111013396000_bib7","doi-asserted-by":"publisher","first-page":"e13313","DOI":"10.1111\/petr.13313","article-title":"Combined liver-kidney transplantation for primary hyperoxaluria type I in children: single center experience","volume":"23","author":"Kotb","year":"2019","journal-title":"Pediatr Transplant"},{"key":"2026033111013396000_bib8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ekir.2021.11.006","article-title":"Long-term transplantation outcomes in patients with primary hyperoxaluria type 1 included in the European Hyperoxaluria Consortium (OxalEurope) registry","volume":"7","author":"Metry","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026033111013396000_bib9","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"key":"2026033111013396000_bib10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int"},{"key":"2026033111013396000_bib11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/ndt\/gfac295","article-title":"Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases","volume":"38","author":"Sellier-Leclerc","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026033111013396000_bib12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ekir.2023.10.004","article-title":"Multicenter long-term real world data on treatment with lumasiran in patients with primary hyperoxaluria type 1","volume":"9","author":"Martin-Higueras","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026033111013396000_bib13","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s00467-022-05836-3","article-title":"Three tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I","volume":"38","author":"Merz","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"2026033111013396000_bib14","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1007\/s00467-019-04330-7","article-title":"Subclinical myocardial disease in patients with primary hyperoxaluria and preserved left ventricular ejection fraction: a two-dimensional speckle-tracking imaging study","volume":"34","author":"Lagies","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2026033111013396000_bib15","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s00467-017-3731-3","article-title":"Systematic assessment of urinary hydroxy-oxo-glutarate for diagnosis and follow-up of primary hyperoxaluria type III","volume":"32","author":"Ventzke","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2026033111013396000_bib16","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1046\/j.1523-1755.1998.00891.x","article-title":"Simultaneous determination of oxalate, citrate and sulfate in children\u2019s plasma with ion chromatography","volume":"53","author":"Hoppe","year":"1998","journal-title":"Kidney Int"},{"key":"2026033111013396000_bib17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026033111013396000_bib18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2026033111013396000_bib19","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/ndt\/gfaa135","article-title":"Effects of oxalobacter formigenes in subjects with primary hyperoxaluria type 1 and end-stage renal disease: a phase II study","volume":"36","author":"Hoppe","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026033111013396000_bib20","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJMc2312941","article-title":"Lumasiran, isolated kidney transplantation, and continued vigilance","volume":"390","author":"Bacchetta","year":"2024","journal-title":"N Engl J Med"},{"key":"2026033111013396000_bib21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1046\/j.1523-1755.1999.00546.x","article-title":"Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure","volume":"56","author":"Hoppe","year":"1999","journal-title":"Kidney Int"},{"key":"2026033111013396000_bib22","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1111\/bcp.14925","article-title":"Therapeutic RNA interference: a novel approach to the treatment of primary hyperoxaluria","volume":"88","author":"Forbes","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026033111013396000_bib23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ekir.2024.10.006","article-title":"Effective newborn screening for type 1 and 3 primary hyperoxaluria","volume":"10","author":"Hoppe","year":"2025","journal-title":"Kidney Int Rep"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf202\/64485040\/gfaf202.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/4\/736\/64485040\/gfaf202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/4\/736\/64485040\/gfaf202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:01:37Z","timestamp":1774969297000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/4\/736\/8272677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,3]]},"published-print":{"date-parts":[[2026,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf202","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,10,3]]}}}